2026-07-22T01:49:51Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/144752025-04-24T18:08:59Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16961

00925njm 22002777a 4500 dc Garcia-Vidal, Carolina author Iglesias-Caballero, Maria author Puerta-Alcalde, Pedro author Mas-Lloret, Vicente author Cuesta-Chasco, Genoveva author Garcia-Pouton, Nicole author Varona Fernandez, Sarai author Pozo Sanchez, Francisco author Vázquez-Morón, Sonia author Marcos, María Ángeles author Soriano, Alex author Casas Flecha, Inmaculada author HEMATOCOVID19-Researchers Group author 2022-03-03 We documented a hematologic patient with prolonged SARS-CoV-2 viral replication in whom emergence of viral mutations was documented after the consecutive use of antivirals and convalescent plasma. The virus detected in the last of 12 clinical samples (day 237) had accumulated 22 changes in amino acids and 29 in nucleotides. Some of these changes, such as the E484Q, were mutations of concern as defined by WHO. This finding represents an enormous epidemiological threat and poses a major clinical challenge. Combined antiviral strategies, as well as specific strategies related to the diagnostic approach of prolonged infections for this specific population, may be needed. Front Microbiol. 2022 Mar 3;13:826883. 10.3389/fmicb.2022.826883 1664-302X Frontiers in Microbiology 35308337 http://hdl.handle.net/20.500.12105/14475 COVID-19 Antivirals Hematology Immunosuppression Mutations Persistence Remdesivir Emergence of Progressive Mutations in SARS-CoV-2 From a Hematologic Patient With Prolonged Viral Replication